ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1582

Long Term Costs and Cost-Effectiveness of an Integrated Rehabilitation Programme for Chronic Knee Pain

Mike Hurley1 and Dr Nicola E. Walsh2, 1School of Rehabilitation Sciences, St George's University of London, London, United Kingdom, 2Allied Health Professions, University of the West of England Bristol, Bristol, United Kingdom

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: exercise, Knee, pain, rehabilitation and self-management

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Rehabilitation Sciences

Session Type: Abstract Submissions (ARHP)

Background/Purpose: Management of chronic knee pain incurs enormous direct and indirect healthcare costs. Enabling Self-management and Coping with Arthritic knee Pain through Exercise (ESCAPE-knee pain) is an integrated rehabilitation programme that, in the short term at least, is more clinically and cost-effectiveness than usual primary care. Unfortunately, the long term costs and cost-effectiveness of the programme is unknown and need to be evaluated. We continued to follow ESCAPE-knee pain participants for 2½ years after completing the programme, to establish the long term knee pain-related costs and cost-effectiveness of the programme.

Methods: 418 participants were randomised to remain on usual primary care or receive the ESCAPE-knee pain programme (individually or groups of 8 participants). Physical function (using WOMAC function sub-score) and knee pain-related health and personal costs (using Client Services Resources Inventory) were assessed at regular time points for 2½ years after completing the programme.
Missing data were imputed using multiple imputation. Mean differences in total cost (95% confidence interval) were obtained from non-parametric bootstrapped linear regression (1000 replications). Costs were estimated from a health and social care perspective in 2003/2004 prices. Costs were discounted at 3.5%.
Cost-effectiveness acceptability curves (CEAC) estimated the probability ESCAPE-knee pain had of greater net monetary benefit compared with usual care, over a range of monetary values a healthcare provider might be prepared to pay for a sustained, clinically meaningful, improvement in function (defined as ≥15% increase from baseline WOMAC-function score) after 2½ years.

Results: 250 participants (60%) were followed-up for 2½ years. Participating on ESCAPE-knee pain cost £224/person (£184-£262). Compared to those who remained on usual care, 2½ years after completing the ESCAPE-knee pain programme a significantly higher proportion (+14%) of participants maintained clinically meaningful improvement in function, and lower health and social care costs. CEAC showed there was a high probability (80-100%) ESCAPE-knee pain was more cost-effective than usual care in producing sustained clinically meaningful improvement in function.

Conclusion: ESCAPE-knee pain is a low-cost intervention with sustained clinical and economic benefits compared to than usual primary care. These conclusions need to be considered given the trial’s high attrition rate and low power. Attrition rates are always high in trials with long term follow-up, and economic outcomes are rarely, if ever, used to power studies. Moreover, given that large-scale, long-term trials are very expensive and complex, few similar studies will be performed and will suffer similar limitations. These results, therefore, are a good estimation of long term clinical and economic outcomes, and contribute to the pool of data from other trials of this chronic condition.


Disclosure:

M. Hurley,
None;

D. N. E. Walsh,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/long-term-costs-and-cost-effectiveness-of-an-integrated-rehabilitation-programme-for-chronic-knee-pain/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology